![Ackman says he would short UnitedHealth, profitability ‘massively overstated'](https://i-invdn-com.investing.com/news/LYNXMPEBBU0PY_S.jpg)
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 2.370 | 2.370 | 0.000 |
Shares | 97.630 | 97.630 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 22.791 | 20.001 |
Price to Book | 5.076 | 4.086 |
Price to Sales | 2.317 | 2.440 |
Price to Cash Flow | 20.297 | 16.387 |
Dividend Yield | 1.266 | 1.366 |
5 Years Earnings Growth | 11.824 | 12.512 |
Number of long holdings: 76
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 9.13 | 840.99 | +1.81% | |
UnitedHealth | US91324P1021 | 7.48 | 536.08 | -1.72% | |
Novo Nordisk B | DK0062498333 | 7.14 | 619.5 | +4.54% | |
Thermo Fisher Scientific | US8835561023 | 3.42 | 578.70 | -0.32% | |
Merck&Co | US58933Y1055 | 3.21 | 89.30 | -1.59% | |
AstraZeneca | GB0009895292 | 2.94 | 11,126.0 | +0.87% | |
Elevance Health | US0367521038 | 2.94 | 400.08 | -0.47% | |
McKesson | US58155Q1031 | 2.79 | 604.84 | +0.25% | |
Boston Scientific | US1011371077 | 2.42 | 105.01 | +1.42% | |
Novartis | CH0012005267 | 2.35 | 98.58 | +3.13% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Belfius Equities Robotics Innova | 1.59B | 13.57 | 2.14 | 14.05 | ||
Belfius Equities Robotics InnovaL | 1.59B | 13.47 | 2.07 | 13.96 | ||
Belfius Equities Robotics Innovat | 1.59B | 13.58 | 2.15 | 14.06 | ||
Belfius Equities Global Health CarL | 725.85M | -1.11 | -2.13 | 5.84 | ||
Belfius Equities Global Health CarC | 725.85M | -1.02 | -2.04 | 5.94 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review